Dyadic International, Inc. DYAI

DYAI Company Overview

Dyadic International, Inc. is a biotechnology company focused on the development and commercialization of proprietary microbial gene expression and protein production platforms for the life sciences industry. The company operates primarily in the biotechnology and biopharmaceutical sectors, with an emphasis on enabling the cost-effective production of vaccines, therapeutic proteins, industrial enzymes, and other biologics. Dyadic’s core technology platform is the proprietary C1 gene expression platform, derived from the thermophilic fungus Myceliophthora thermophila, which is engineered to produce high volumes of proteins rapidly and at lower manufacturing costs compared with certain conventional systems.

The company’s primary revenue drivers have historically included licensing agreements, research collaborations, milestone payments, and government-supported development initiatives tied to biologics manufacturing and vaccine research. Dyadic serves biotechnology companies, pharmaceutical manufacturers, vaccine developers, and research institutions across global healthcare markets. The company traces its origins to enzyme technology development in the 1970s and later evolved into a biotechnology platform company following the divestiture of its industrial enzyme business to DuPont in 2015. Since then, Dyadic has concentrated on expanding the commercial and scientific applications of the C1 platform in human and animal health.